<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="6843"><DrugName>TGF-beta 2, Genzyme/Celtrix</DrugName><DrugSynonyms><Name><Value>BetaKine</Value></Name><Name><Value>PEG-TGF-beta2</Value></Name><Name><Value>TGF-beta2, Santen</Value></Name><Name><Value>TGF-beta2, Celtrix</Value></Name><Name><Value>PEG-TGF-beta2, Enzon</Value></Name><Name><Value>PEG-TGF-beta2, Celtrix</Value></Name><Name><Value>TGF-beta 2, Genzyme/Celtrix</Value></Name></DrugSynonyms><CompanyOriginator id="15342">Celtrix Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="15342">Celtrix Pharmaceuticals Inc</Company><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Company id="24618">Sanofi Cell Therapy and Regenerative Medicine Business</Company><Company id="28462">Sanofi Biosurgery</Company></CompaniesSecondary><CrossReferences><SourceEntity id="6843" type="Drug"><TargetEntity id="203416" type="siDrug">rTGF-beta2</TargetEntity></SourceEntity><SourceEntity id="15342" type="Company"><TargetEntity id="4295905901" type="organizationId">Celtrix Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="19670" type="Company"><TargetEntity id="4295877908" type="organizationId">Santen Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="24618" type="Company"><TargetEntity id="5035523888" type="organizationId">Genzyme Tissue Repair</TargetEntity></SourceEntity><SourceEntity id="28462" type="Company"><TargetEntity id="4295902793" type="organizationId">Genzyme Biosurgery Corp</TargetEntity></SourceEntity><SourceEntity id="1226" type="ciIndication"><TargetEntity id="4830" type="siCondition"/></SourceEntity><SourceEntity id="241" type="ciIndication"><TargetEntity id="10061128" type="MEDDRA"/><TargetEntity id="D005131" type="MeSH"/><TargetEntity id="-593450985" type="omicsDisease"/><TargetEntity id="2690" type="siCondition"/></SourceEntity><SourceEntity id="288" type="ciIndication"><TargetEntity id="10038923" type="MEDDRA"/><TargetEntity id="D012164" type="MeSH"/><TargetEntity id="-422908255" type="omicsDisease"/><TargetEntity id="794" type="siCondition"/><TargetEntity id="1944" type="siCondition"/></SourceEntity><SourceEntity id="347" type="ciIndication"><TargetEntity id="D014945" type="MeSH"/></SourceEntity><SourceEntity id="372" type="ciIndication"><TargetEntity id="10045285" type="MEDDRA"/><TargetEntity id="D014456" type="MeSH"/><TargetEntity id="413" type="siCondition"/></SourceEntity><SourceEntity id="723" type="ciIndication"><TargetEntity id="10040943" type="MEDDRA"/><TargetEntity id="D012883" type="MeSH"/><TargetEntity id="-1807650329" type="omicsDisease"/><TargetEntity id="497" type="siCondition"/></SourceEntity><SourceEntity id="790" type="ciIndication"><TargetEntity id="10056340" type="MEDDRA"/><TargetEntity id="D017719" type="MeSH"/><TargetEntity id="-1424289263" type="omicsDisease"/><TargetEntity id="495" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="PTGT-01834" type="ciTarget"><TargetEntity id="153860182170423" type="siTarget">Transforming growth factor beta-2</TargetEntity><TargetEntity id="4567" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1226">Age related macular degeneration</Indication><Indication id="241">Ocular injury</Indication><Indication id="288">Retinopathy</Indication><Indication id="347">Wound healing</Indication><Indication id="372">Ulcer</Indication><Indication id="723">Skin ulcer</Indication><Indication id="790">Diabetic foot ulcer</Indication></IndicationsSecondary><ActionsPrimary><Action id="3700">TGF beta 2 ligand</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="611">Dermatological formulation</Technology><Technology id="80">Peptide</Technology></Technologies><LastModificationDate>2017-08-29T04:52:00.000Z</LastModificationDate><ChangeDateLast>2016-10-27T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="28462" linkType="Company"&gt;Genzyme Biosurgery&lt;/ulink&gt; (formerly &lt;ulink linkID="24618" linkType="Company"&gt;Genzyme Tissue Repair&lt;/ulink&gt;, GTR) under  license from &lt;ulink linkID="15342" linkType="Company"&gt;Celtrix&lt;/ulink&gt;, was developing recombinant TGF-beta-2 (BetaKine), for the potential treatment of wound healing and systemic disease [&lt;ulink linkID="296889" linkType="reference"&gt;296889&lt;/ulink&gt;], [&lt;ulink linkID="438354" linkType="reference"&gt;438354&lt;/ulink&gt;]. By August 1999, GTR had completed phase II clinical trials, for the treatment of diabetic foot ulcers [&lt;ulink linkID="317150" linkType="reference"&gt;317150&lt;/ulink&gt;], [&lt;ulink linkID="338443" linkType="reference"&gt;338443&lt;/ulink&gt;]. In March 1998, analysts at Banc of America reported that phase I trials had commenced for multiple sclerosis [&lt;ulink linkID="283196" linkType="reference"&gt;283196&lt;/ulink&gt;]. By August 1999, GTR was seeking to outlicense certain rights to the program [&lt;ulink linkID="338443" linkType="reference"&gt;338443&lt;/ulink&gt;]. In December 2001, TGF-beta-2 continued to feature on Genzyme's pipeline [&lt;ulink linkID="438354" linkType="reference"&gt;438354&lt;/ulink&gt;]; however,  the program was no longer listed by April 2002 [&lt;ulink linkID="577796" linkType="Reference"&gt;577796&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Celtrix was also developing the compound for the treatment of ophthalmic conditions; however, this indication was discontinued in 1991 following disappointing phase II results [&lt;ulink linkID="174193" linkType="reference"&gt;174193&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In August 1999, GTR reported the successful completion of a phase II trial to evaluate TGF-beta-2 as a treatment for diabetic foot ulcers. TGF-beta-2 showed statistically significant improvement in achieving wound closure versus placebo in a phase II study of 177 diabetic patients. The data were collected over a period of three years in a 15 center, double-blinded, randomized, placebo controlled clinical trial [&lt;ulink linkID="338443" linkType="reference"&gt;338443&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;By March 1995, Celtrix was collaborating with the US &lt;ulink linkID="20519" linkType="Company"&gt;National Cancer Institute&lt;/ulink&gt; in evaluating TGF-beta-2 in early phase I clinical trials for oral mucositis, a side effect of cytotoxic cancer therapy [&lt;ulink linkID="205485" linkType="reference"&gt;205485&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Also by March 1995, Celtrix had a research collaboration with Santen whereby Santen was evaluating BetaKine for the potential treatment of retinal eye disorders in Japan [&lt;ulink linkID="205485" linkType="reference"&gt;205485&lt;/ulink&gt;]. Santen had terminated the agreement by September 1996 [&lt;ulink linkID="218851" linkType="reference"&gt;218851&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Celtrix had discontinued development of a polyethylene glycol (PEG) conjugate of TGF beta-2 for potential use in the treatment of cancer. The conjugate was licensed from Enzon in 1993 [&lt;ulink linkID="169596" linkType="reference"&gt;169596&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="288">Retinopathy</Indication><StatusDate>1996-09-09T00:00:00.000Z</StatusDate><Source id="218851" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28462">Sanofi Biosurgery</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>2002-04-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28462">Sanofi Biosurgery</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="723">Skin ulcer</Indication><StatusDate>2002-04-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15342">Celtrix Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="241">Ocular injury</Indication><Source id="174193" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15342">Celtrix Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="347">Wound healing</Indication><StatusDate>1998-02-05T00:00:00.000Z</StatusDate><Source id="277051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15342">Celtrix Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="372">Ulcer</Indication><StatusDate>1998-02-05T00:00:00.000Z</StatusDate><Source id="277051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15342">Celtrix Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1226">Age related macular degeneration</Indication><Source id="174193" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="288">Retinopathy</Indication><StatusDate>1995-03-31T00:00:00.000Z</StatusDate><Source id="205485" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15342">Celtrix Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="347">Wound healing</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15342">Celtrix Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="372">Ulcer</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28462">Sanofi Biosurgery</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="723">Skin ulcer</Indication><StatusDate>1999-03-03T00:00:00.000Z</StatusDate><Source id="317150" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28462">Sanofi Biosurgery</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>1999-03-03T00:00:00.000Z</StatusDate><Source id="317150" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24618">Sanofi Cell Therapy and Regenerative Medicine Business</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="723">Skin ulcer</Indication><StatusDate>1998-02-05T00:00:00.000Z</StatusDate><Source id="277051" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24618">Sanofi Cell Therapy and Regenerative Medicine Business</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="790">Diabetic foot ulcer</Indication><StatusDate>1998-02-05T00:00:00.000Z</StatusDate><Source id="277051" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15342">Celtrix Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1226">Age related macular degeneration</Indication><AwardedIndication>Treatment of full thickness macular holes.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>1992-12-18T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01834"><Name>TGF beta-2 ligand</Name><SwissprotNumbers><Swissprot>P09858</Swissprot><Swissprot>P17247</Swissprot><Swissprot>P21214</Swissprot><Swissprot>P27090</Swissprot><Swissprot>P30371</Swissprot><Swissprot>P61811</Swissprot><Swissprot>P61812</Swissprot><Swissprot>Q07257</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009547">Sanofi SA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19670">Santen Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23330">Insmed Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="2">Drug - Screening/Evaluation</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="117171" title="Santen to evaluate Celtrix's BetaKine for retinal eye disease in Japan"/><Deal id="117172" title="GTR to develop Celtrix's TGF-beta-2 worldwide"/><Deal id="124845" title="Celtrix and National Cancer Institute to evaluate TGF-beta-2 for oral mucositis"/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>